$ENSC News
Last published 3w ago
- 3w agoENSCEnsysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, DubaiACCESS Newswire~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~ SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc.
- 1mo agoENSCEnsysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRAACCESS Newswire~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc.
- 1mo agoENSCEnsysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug RegulationACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. a clinical-stage biotechnology company developing novel neuroplastogenic
- 1mo agoENSCEnsysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic DrugsACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. a clinical-stage biotechnology company developing novel neuroplastogenic
- 2mo agoENSCEnsysce Biosciences Announces Upcoming Conference and Industry Event ParticipationACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. a clinical-stage biotechnology company developing novel neuroplastogenic
- 2mo agoENSCEnsysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical StudyACCESS Newswire~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc.
- 2mo agoENSCEnsysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 SymposiumACCESS Newswire~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome ~~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch
- 3mo agoENSCEnsysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsACCESS NewswireAcquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18,
- 3mo agoCLRONTHIIOVAENSC+1Why Investors Are Watching These Healthcare MoversGlobeNewswireDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ:CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in
- 3mo agoENSCEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private FinancingACCESS NewswireAcquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome Up to $77 million in private financing consisting of $21.5
- 4mo agoENSCEnsysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal GrantACCESS NewswireFunds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc. ("Ensysce" or the
- 4mo agoENSCEnsysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical StudyACCESS Newswire~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Ensysce Biosciences, Inc.
- 6mo agoENSCEnsysce Biosciences Reports First Quarter 2026 Financial ResultsACCESS Newswire~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~~ Company Launches Formal Review of Strategic
- 6mo agoENSCEnsysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection TechnologyACCESS Newswire~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical company
- 6mo agoENSCEnsysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in AmsterdamACCESS Newswire~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical company
- 6mo agoENSCEnsysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical StudyACCESS Newswire~ Advances First-in-Class Opioid with Oral Overdose-Protection ~SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical
- 7mo agoENSCEnsysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain ProgramsACCESS Newswire~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. ("Ensysce"
- 7mo agoENSCEnsysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial ResultsACCESS Newswire~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. ("Ensysce" or
- 8mo agoENSCEnsysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future PlansACCESS Newswire~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 / Ensysce Biosciences,
- 8mo agoENSCEnsysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) TechnologyACCESS Newswire~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc.
- 8mo agoENSCKBLBPLTRRXTFollow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet StrengthGlobeNewswireDENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation,
- 8mo agoENSCEnsysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder ValueACCESS NewswireReview Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysce Biosciences,
- 8mo agoENSCEnsysce Biosciences Invited to Participate in Upcoming Scientific and Industry EventsACCESS Newswire~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / Ensysce Biosciences,
- 9mo agoENSCEnsysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute PainACCESS Newswire~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. , a clinical-stage
- 10mo agoENSCEnsysce Biosciences Issues Annual Shareholder LetterACCESS NewswirePF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market LaunchFDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale UpMPAR® Patent Protection Extended Through 2042Up to $20
- 11mo agoENSCDiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)GlobeNewswireNew York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc.
- 11mo agoENSCEnsysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation OpioidACCESS Newswire~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 / Ensysce Biosciences, Inc. ("Ensysce" or the
- 11mo agoENSCEnsysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection TechnologyACCESS Newswire~ New U.S. Patent Extends Protection Through 2042 ~~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR® ~ SAN DIEGO, CA / ACCESS Newswire / December 2, 2025 / Ensysce Biosciences,
- 11mo agoENSCEnsysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing ApproachACCESS Newswire~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. , a
- 11mo agoENSCEnsysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain ProgramsACCESS Newswire~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc.
- 11mo agoENSCDiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)GlobeNewswireNew York, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc.
- 12mo agoENSCEnsysce Biosciences Reports Third Quarter 2025 Financial ResultsACCESS Newswire~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~~ Further Program Advancement Supported by Preferred Stock
- 1y agoENSCEnsysce Biosciences Releases Symposium Highlights from PAINWeek 2025ACCESS Newswire~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. , a
- 1y agoENSCEnsysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 SymposiumACCESS Newswire~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. ("Ensysce" or the
- 1y agoENSCEnsysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025ACCESS Newswire~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~~ Ensysce Biopharma Leader to Deliver Opening Remarks and
- 1y agoENSCDiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)GlobeNewswireNew York, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc.
- 1y agoENSCEnsysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program UpdatesACCESS NewswireInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Protection
- 1y agoENSCEnsysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA FeedbackACCESS Newswire~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505 Regulatory Strategy ~~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits are Recognized
- 1y agoENSCEnsysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce AbuseACCESS Newswire~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. ("Ensysce" or the
- 1y agoENSCEnsysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2ACCESS Newswire~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences,
- 1y agoENSCEnsysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025ACCESS Newswire~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. , a clinical-stage
- 1y agoENSCEnsysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose ProtectionACCESS Newswire~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc.
- 1y agoENSCEnsysce Biosciences Reports First Quarter 2025 Financial ResultsACCESS NewswireReceives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce
- 1y agoENSCEnsysce Biosciences Bolsters Management Team with Regulatory ExpertACCESS Newswire~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical
- 1y agoENSCEnsysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while
- 1y agoENSCEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsACCESS NewswireSAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief
- 1y agoENSCEnsysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use DisorderACCESS Newswire~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc.
- 1y agoENSCEnsysce Biosciences Announces Positive Data from Opioid Overdose Protection StudyACCESS Newswire~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. ("Ensysce" or
- 1y agoENSCEnsysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical company developing innovative solutions for
- 1y agoENSCEnsysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in PainACCESS Newswire~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc.